Obesity
23 videos · last 6 months shuffled daily, then older videos newest first
▶
1:46:58 From Wellness App to Digital Health Application: Building a Digital Therapeutic in Europe - E5
GCP-Mindset's Beyond Outcomes talks to Vitadio co-founder Lenka Šomvárska about generating clinical evidence, CE marking and the MDR transition for a type 2 diabetes digital therapeutic.
▶
19:54 Breast Cancer Trials at ASCO 2026: BWEL, lidERA and More
Komen Scholars Jennifer Ligibel, MD, of Dana-Farber and Mariana Chavez MacGregor, MD, of MD Anderson, with Elizabeth McDonald, MD, discuss ASCO 2026 breast cancer trials including BWEL, OPTIMA, lidERA, persevERA and evERA, for Susan G. Komen.
▶
2:56 New Data Released on Weight Loss Drug Retatrutide
ABC News chief medical correspondent Dr. Tara Narula explains what to know about retatrutide and the latest clinical trial results.
▶
5:22 TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity
New Phase 3 TRIUMPH-2 data suggest retatrutide produces substantial weight loss alongside glycemic improvement in people with type 2 diabetes.
▶
9:53 ASCO 2026: Breast Cancer Weight Loss (BWEL) Trial
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute discuss new research from the Breast Cancer Weight Loss (BWEL) trial, along with lifestyle, diet and GLP-1 agonists.
▶
25:22 Can GLP-1 Drugs Really Help to Prevent Cancer?
The hosts explore new ASCO 2026 research suggesting GLP-1 drugs may reduce cancer risk and improve outcomes after diagnosis, and explain why the findings still need prospective clinical trials before they change practice.
▶
9:25 Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3
Diana Isaacs, PharmD, and Natalie Bellini, DNP, on topline Phase 3 TRIUMPH-3 results for retatrutide, a triple agonist, in adults with obesity.
▶
15:16 The Imaging Gap in GLP-1 Trials
Prof. Mikael Boesen of Copenhagen University Hospital discusses why GLP-1 knee osteoarthritis trials still enrol patients on 1957 x-ray grading, and when sponsors should use DXA or MRI to measure joint and muscle changes, on The Clinical Trial Vanguard.
▶
1:00:25 Optimizing Obesity Endpoints: Early Innovation to Late Differentiation
Clario's eCOA, cardiac safety and medical imaging experts discuss choosing endpoints for obesity drug trials, from early signals that inform dose selection to evidence packages for regulators.
▶
10:37 The Evidence Suggesting GLP-1s Can Curb Drug and Alcohol Cravings
PBS NewsHour's William Brangham reports on researchers testing whether GLP-1 drugs can curb people's cravings for drugs and alcohol.
▶
46:41 Moonwalk's Alex Aravanis on siRNA Obesity Drugs Beyond GLP-1s
Moonwalk Biosciences CEO Alex Aravanis, M.D., Ph.D., discusses the company's adipose-targeted siRNA approach to obesity beyond GLP-1s, its $70 million Series B and what it takes to build a clinical-stage company, on Life Science Connect's Business of Biotech.
▶
11:18 The Next Generation of GLP-1 Weight Loss Drugs
STAT reviews how Pfizer, Boehringer Ingelheim, Viking Therapeutics, AstraZeneca and others are developing weight-loss drugs to compete with Novo Nordisk and Eli Lilly, whose next candidates include CagriSema, orforglipron and retatrutide.
▶
52:06 The Latest Therapeutic Developments for Type 1 Diabetes Post-ADA
Piper Sandler analyst Ted Tenthoff and Joslin Diabetes Center's Dr. Rohit Kulkarni discuss type 1 diabetes data from ADA 2026, including teplizumab, beta cell regeneration and menin inhibition.
▶
39:57 AAIC 2026 Findings for Familial Alzheimer's Families
Youngtimers reviews findings from AAIC 2026 and the DIAD Family Conference for familial Alzheimer's families, including results for tau drugs E2814 and diranersen, blood tests and prevention trials starting earlier.
▶
9:28 Obesity With Mortality and Bleeding in Cancer-Associated VT
Álvaro Dubois-Silva, MD, and Marijan Bosevski, MD, PhD, discuss their Mayo Clinic Proceedings cohort study from the RIETE registry linking obesity to lower mortality and higher bleeding risk in cancer-associated venous thromboembolism.
▶
2:30 Retatrutide Weight-Loss Trial Results
Dr. Céline Gounder reports for CBS Mornings on clinical trial results for retatrutide, an experimental weight-loss drug that had not been approved by the FDA as of September 2026.
▶
13:24 A New Class of Weight Loss Drugs Including Ozempic and Wegovy Spark Interest
A video by 60 Minutes looks at the effects of obesity from weight loss drugs Ozempic and Wegovy in this video.
▶
30:56 Repurposed Drugs in Progressive MS Research
Ellen Mowry, Wee Yong and Laura Airas discuss International Progressive MS Alliance projects repurposing existing drugs: GLP-1 receptor agonists, salbutamol with ibudilast, and a hydroxychloroquine trial, for the MS International Federation.
▶
4:48 Amgen Shares Sinking After Clinical Trial
Biopharma giant Amgen shares sliding on bone density data in this CNBC video.
▶
5:53 Roche's Head of Cardiovascular Disease Dissects GLP-1 Drug Trial Results
Manu Chakravarthy, Roche SVP and global head of cardiovascular disease, discusses the company's recent weight-loss drug trial results on CNBC's Fast Money.
▶
15:02 GLP-1 Trials Have an Imaging Problem
Professor Mikael Boesen of Copenhagen University Hospital on GLP-1 knee osteoarthritis trials still enrolling patients from a 1957 radiograph, while the tissue the drug acts on goes unmeasured.
▶
4:29 Eli Lilly CEO on Tirzepatide Trial Results and Q1 Earnings
Eli Lilly CEO David Ricks discusses the company's latest earnings and its clinical trial results for the weight-loss drug tirzepatide, on CNBC's Squawk Box.
▶
39:28 New Obesity Trial Results Change Everything! Inside the Data with Fractyl Health CEO
Christopher Durham talks to Harith Rajagopalan, MD, PhD, cardiologist and CEO of Fractyl Health, about new obesity trial results and what happens to patients after GLP-1s.